Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)

Haematologica

Volumn 99, Issue 9, 2014, Pages 1479-1485

  Jaccard, Arnaud ^a   Comenzo, Raymond L ^b   Hari, Parameswaran ^c   Hawkins, Philip N ^d   Roussel, Murielle ^e   Morel, Pierre ^f   Macro, Margaret ^g   Pellegrin, Jean Luc ^h   Lazaro, Estibaliz ^h   Mohty, Dania ^a   Mercie, Patrick ^h   Decaux, Olivier ⁱ   Gillmore, Julian ^d   Lavergne, David ^a   Bridoux, Frank ^j   Wechalekar, Ashutosh D ^d   Venner, Christopher P ^d,k  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b TUFTS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f Hematology Unit   (France)

^g CAEN UNIVERSITY HOSPITAL   (France)

^h BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁱ RENNES UNIVERSITY HOSPITAL   (France)

^j POITIERS UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BENDAMUSTINE; BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; TROPONIN I; TROPONIN T; BORONIC ACID DERIVATIVE; PROTEIN AGGREGATE; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HEART AMYLOIDOSIS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE SEPTUM; HIGH RISK POPULATION; HUMAN; LIGHT CHAIN DEPOSITION DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPATHY; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PROTEINURIA; RETROSPECTIVE STUDY; SEPSIS; SUDDEN CARDIAC DEATH; TREATMENT RESPONSE; AMYLOIDOSIS; BLOOD; CARDIOMYOPATHIES; CHEMISTRY; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; MIDDLE AGED; MORTALITY; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; BORONIC ACIDS; CARDIOMYOPATHIES; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; PROTEIN AGGREGATES; PYRAZINES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84907321417     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.104109     Document Type: Article

References (26)

1. Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86(2):180-6.
2. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-7.
3. Dietrich S, Schonland SO, Benner A, Bochtler T, Kristen AV, Beimler J, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood. 2010;116(4):522-8.
4. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14): 1924-33.
5. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121 (17):3420-7.
6. Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophosphamide, velcade and dexam-ethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica. 2007;92(8):1149-50.
7. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 2008;93(2):295-8.
8. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009;114(8):1489-97.
9. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, et al. Bortezomib with or without dexametha-sone in primary systemic (light chain) amy-loidosis. J Clin Oncol. 2010;28(6): 1031-7.
10. Zonder J, Sanchorawala V, Snyder R, Matous J, Terebelo H, Janakirama N, et al. Rapid haematologic and organ responses in patients with AL amyloid treated with bortezomib plus melphalan and dexam-ethasone. Amyloid Journal of Protein Folding Disorders. 2010;17(s1):86-7.
11. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, et al. Efficacy and safety of once-weekly and twice- weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4): 865-73.
12. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexam-ethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19): 4391-4.
13. Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, et al. Cyclophosphamide, bortezomib, and dex-amethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387-90.
14. Gertz MA, Comenzo R, Falk RH, Fermand J-P, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005;79(4):319-28.
15. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30 (36):4541-9.
16. Kristen AV, Giannitsis E, Lehrke S, Hegenbart U, Konstandin M, Lindenmaier D, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood. 2010;116 (7):2455-61.
17. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337-41.
18. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Laumann K, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010;115(16):3416-7.
19. Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexam-ethasone, cyclophosphamide, and lenalido-mide in previously untreated multiple myeloma. Blood. 2012;119(19):4375-82.
20. Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86(1):12-8.
21. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012;119(21):4860-7.
22. Dinner S, Witteles W, Afghahi A, Witteles R, Arai S, Lafayette R, et al. Lenalidomide, mel-phalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica. 2013;98 (10):1593-9.
23. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloido-sis. Blood. 2012;119 (23):5384-90.
24. Mollee P, Tiley C, Cunningham I, Moore J, Prince HM, Cannell P, et al. A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. Br J Haematol. 2012;157(6):766-9.
25. Sachchithanantham S, Mahmood S, Sayed R, Patel K, Fontana M, Lane T, et al. Biweekly bortezomib is more efficacious than weekly bortezomib when used as first line in patients with systemic AL amyloido-sis. Blood (ASH Annual Meeting Abstracts) 2013;122:Abstract 1981.
26. Warsame R, Bang S, Kumar S, Lacy, M, Buadi F, Dingli D et al. Outcomes and treatments of relapsed AL amyloidosis following stem cell transplant. Blood (ASH Annual Meeting Abstracts) 2012;120: Abstract 1858.